Items Tagged ‘oncotype dx’

October 8th, 2015

Low Oncotype® Recurrence Score® Identifies Group of Women with Early Stage Breast Cancer That can Avoid Chemotherapy

By

The results of a study presented at the European Cancer Congress demonstrate that early-stage breast cancer patients with a low Oncotype DX® Recurrence Score® result of 10 or less who received hormonal therapy alone without chemotherapy had less than a one percent chance of distant recurrence at five years. The results are the first to be […]

View full entry

Tags: Breast Cancer, clinical trial, early-stage breast cancer, News, oncotype dx, Stage I Node Negative Breast Cancer, Tailorx, Trial Assigning Individualized Options for Treatment (Rx)


August 11th, 2014

Large Independent Validation Study Validates Oncotype DX Prostate Cancer Test

By

Genomic Health, Inc. announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX® Genomic Prostate Score (GPS) predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer.  This study validated the Oncotype DX prostate cancer […]

View full entry

Tags: Early Stage I-II (A-B) Prostate Cancer, News, oncotype, oncotype dx, Prostate Cancer, risk recurrence